

# APG-20 Metreleptin

**Purpose:** This study is being done to see whether a medication called metreleptin, also known as the study medication/treatment, is safe and works in patients with familial partial lipodystrophy (FPLD).

**What Is Involved:** If you decide you would like to participate in the study, you can expect to be in the study for a minimum of 16.5 months. There are 11 in-person visits and 1 phone call

## Invasive Activities

Blood sample collection

## Non-invasive Activities

Physical examination, Urine collection, DXA scan, Liver ultrasound, Echocardiogram, ECG, Questionnaires, Dietary counseling

**Inclusion Criteria:** At least 18 years of age, Diagnosis of FPLD, and more....

**Exclusion Criteria:** Previous treatment with Metreleptin, Leptin greater than 20, APL, and more....

## **Principal Investigator:**

Bradley Javorsky, MD  
Dept. of Medicine  
Division of Endocrinology and Molecular Medicine  
262-253-7155  
Bjavorsky@mcw.edu